Remove 2010 Remove Leads Remove Pharmaceutical products
article thumbnail

Leading innovators in ssRNA virus peptides for the pharmaceutical industry

Pharmaceutical Technology

Patent volumes related to ssRNA virus peptides Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Johnson & Johnson 419 Unlock company profile GSK 419 Unlock company profile C. J&J develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products.

article thumbnail

Leading innovators in HIV peptides for the pharmaceutical industry

Pharmaceutical Technology

Johnson & Johnson researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. ‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leading innovators in lipase compositions for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Lipase compositions is a key innovation area in pharmaceuticals Lipases belong to a class of hydrolase enzymes, which help in the hydrolysis of triglycerides and break them down into free fatty acids and glycerol.

article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

The paper, by a team from Imperial College London, concluded that the FDA gave the go ahead to 95% of the 89 products approved between 2010 and 2019 before EMA, with the Europeans trailing the Americans by a median of 241 days. Between 2012 and 2020, it averaged 3% each year, whereas Spain’s share, for example, had increased from 2.6%

article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.

Pharma 97
article thumbnail

The rise and rise of ESG in the pharmaceutical sector – is a zero-waste supply?chain possible?? 

Pharmaceutical Technology

Firms in the pharmaceutical industry – as with those in many advanced sectors – have become increasingly preoccupied with environmental, social and governance (ESG) goals in recent years. Household names are leading the way. Figure 1: Social media posts from pharmaceutical firms mentioning “environment”. Source: GlobalData.